EA200100925A1 - Применение глицинбетаина в качестве антитромботического средства - Google Patents
Применение глицинбетаина в качестве антитромботического средстваInfo
- Publication number
- EA200100925A1 EA200100925A1 EA200100925A EA200100925A EA200100925A1 EA 200100925 A1 EA200100925 A1 EA 200100925A1 EA 200100925 A EA200100925 A EA 200100925A EA 200100925 A EA200100925 A EA 200100925A EA 200100925 A1 EA200100925 A1 EA 200100925A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- glycine betaine
- relates
- therapeutic
- blood clots
- glycinbetaine
- Prior art date
Links
- 239000003146 anticoagulant agent Substances 0.000 title abstract 2
- 229960004676 antithrombotic agent Drugs 0.000 title 1
- 229960003237 betaine Drugs 0.000 abstract 5
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 abstract 5
- 208000007536 Thrombosis Diseases 0.000 abstract 2
- 230000000069 prophylactic effect Effects 0.000 abstract 2
- 230000001225 therapeutic effect Effects 0.000 abstract 2
- 208000032843 Hemorrhage Diseases 0.000 abstract 1
- 208000024659 Hemostatic disease Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 229940127219 anticoagulant drug Drugs 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000034158 bleeding Diseases 0.000 abstract 1
- 230000000740 bleeding effect Effects 0.000 abstract 1
- 238000004555 blood preservation Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000008506 pathogenesis Effects 0.000 abstract 1
- 230000035755 proliferation Effects 0.000 abstract 1
- 230000009424 thromboembolic effect Effects 0.000 abstract 1
- 208000019553 vascular disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Materials For Medical Uses (AREA)
- Medicinal Preparation (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Compounds Of Unknown Constitution (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
В заявке описано применение глицинбетаина для лечения физиопатологических сосудистых болезней. Изобретение относится к применению глицинбетаина в качестве лечебного и профилактического средства при патогенезе тромбоэмболических и гемостатических болезней артериального или венозного происхождения. Глицинбетаин обладает профилактической активностью, предупреждая образование тромбов, и лечебной активностью, ингибируя пролиферацию тромбов путем их разрушения. Изобретение отличается тем, что применение глицинбетаина не связано с каким-либо риском возникновения кровотечения или развитием аллергии в отличие от применяемых в настоящее время соединений и методов лечения. Изобретение также относится к применению глицинбетаина в качестве антикоагулянта для консервации крови.Международная заявка была опубликована вместе с отчетом о международном поиске.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE9900144A BE1012495A3 (fr) | 1999-03-02 | 1999-03-02 | La glycine-betaine pour son usage antithrombotique. |
PCT/BE2000/000021 WO2000051596A1 (fr) | 1999-03-02 | 2000-03-01 | La glycine betaïne pour son usage antithrombotique |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200100925A1 true EA200100925A1 (ru) | 2002-04-25 |
EA004047B1 EA004047B1 (ru) | 2003-12-25 |
Family
ID=3891794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200100925A EA004047B1 (ru) | 1999-03-02 | 2000-03-01 | Применение глицинбетаина в качестве антитромботического средства |
Country Status (20)
Country | Link |
---|---|
US (1) | US6855734B2 (ru) |
EP (1) | EP1156796B1 (ru) |
JP (1) | JP2002538113A (ru) |
KR (1) | KR100767270B1 (ru) |
CN (1) | CN1194681C (ru) |
AT (1) | ATE311226T1 (ru) |
AU (1) | AU2897900A (ru) |
BE (1) | BE1012495A3 (ru) |
BR (1) | BR0008631A (ru) |
CA (1) | CA2362558C (ru) |
DE (1) | DE60024415T2 (ru) |
EA (1) | EA004047B1 (ru) |
ES (1) | ES2254144T3 (ru) |
HK (1) | HK1044276B (ru) |
HU (1) | HUP0105397A3 (ru) |
IL (1) | IL145068A0 (ru) |
MX (1) | MXPA01008426A (ru) |
NZ (1) | NZ513905A (ru) |
PL (1) | PL204560B1 (ru) |
WO (1) | WO2000051596A1 (ru) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUP9900213A1 (hu) * | 1999-02-01 | 2000-12-28 | Gábor Bogye | Gyógykompozíció(k) gesztagén tipusú hormon tartalmú gyógyszerek thromb-embóliás mellékhatásainak mérséklésére |
US7608640B2 (en) | 1999-03-02 | 2009-10-27 | Jallal Messadek | Glycine betaine and its use |
DK1408949T3 (da) * | 2001-02-05 | 2008-04-28 | Jallal Messadek | Glycinbetain og dets brugområde for opfindelsen |
BE1015608A6 (fr) | 2003-07-15 | 2005-06-07 | Messadek Jallal | Traitement des arterites. |
US20060160896A1 (en) * | 2002-02-04 | 2006-07-20 | Jallal Messadek | Therapeutic treatment |
JP2005518453A (ja) * | 2002-02-25 | 2005-06-23 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 二極性トランスカロテノイド塩およびそれらの使用 |
US7759506B2 (en) | 2002-02-25 | 2010-07-20 | Diffusion Pharmaceuticals Llc | Bipolar trans carotenoid salts and their uses |
AU2002343174A1 (en) * | 2002-11-25 | 2004-06-18 | Rachid Ennamany | Betaine and salicylic acid compositions |
US8697679B2 (en) | 2003-03-07 | 2014-04-15 | N.V. Nutricia | Method and composition for treating or preventing catabolism or stimulating anabolism in a mammal undergoing metabolic stress |
EP1615632B1 (fr) * | 2003-04-17 | 2006-12-06 | Jallal Messadek | Formulations orales flottantes pour la liberation controlee de la betaine |
CA2575760A1 (en) * | 2003-08-04 | 2005-02-10 | Jallal Messadek | Selected betaines and their uses |
BE1016128A6 (fr) * | 2004-07-22 | 2006-03-07 | Messadek Jallal | Combinaisons therapeutiques |
WO2006050581A2 (en) | 2004-11-10 | 2006-05-18 | Jallal Messadek | Betaine as agent against arthropod - or mosquito -borne diseases |
WO2006086856A1 (en) | 2005-02-15 | 2006-08-24 | Messadek, Jallal | Combination therapeutic compositions and method of use |
CN101180257A (zh) | 2005-02-24 | 2008-05-14 | 扩散药品有限公司 | 反式类胡萝卜素、其合成、制剂和用途 |
ATE540690T1 (de) | 2005-04-27 | 2012-01-15 | Jallal Messadek | Insulinkombinationen |
US9597311B2 (en) * | 2005-09-27 | 2017-03-21 | Robert Benson Aylor | Suppression and prevention of tumors |
US8557863B2 (en) * | 2005-09-27 | 2013-10-15 | Robert Benson Aylor | Suppression and prevention of tumors |
EA200970944A1 (ru) | 2007-04-13 | 2010-06-30 | Диффьюжн Фармасьютикалз Ллс | Применение биполярных транскаротиноидов в качестве предварительного лечения при лечении заболевания периферических сосудов |
CA2703946A1 (en) * | 2007-10-31 | 2009-05-07 | Diffusion Pharmaceuticals Llc | A new class of therapeutics that enhance small molecule diffusion |
WO2009065193A1 (en) * | 2007-11-21 | 2009-05-28 | Jallal Messadek | Treatment of aspirin resistance with betaine and/or betaine enriched molasses |
AU2010263245A1 (en) | 2009-06-22 | 2012-01-19 | Diffusion Pharmaceuticals Llc | Diffusion enhancing compounds and their use alone or with thrombolytics |
CN103124498A (zh) | 2010-06-02 | 2013-05-29 | 扩散药品有限公司 | 双极性反式类胡萝卜素的口服制剂 |
JP7032320B2 (ja) | 2016-03-24 | 2022-03-08 | ディフュージョン・ファーマシューティカルズ・エルエルシー | 癌を処置するための、化学療法及び放射線療法を伴う二極性トランスカロテノイドの使用 |
CN109342606B (zh) * | 2018-12-05 | 2021-11-02 | 宁波市产品食品质量检验研究院(宁波市纤维检验所) | 一种水产品中甘氨酸甜菜碱的检测方法 |
US11285349B1 (en) * | 2019-10-07 | 2022-03-29 | TFS Holdings, LLC | Sprinkler system antifreeze compositions and methods |
CN111505131B (zh) * | 2020-01-02 | 2023-03-31 | 东莞东华医院有限公司 | 基于血清代谢组学改变建立的预测冠心病斑块不稳定性临床模型 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4980277A (en) * | 1987-10-16 | 1990-12-25 | Cultor Ltd. | Cryoprotectant solution and method |
HU210122B (en) | 1988-03-23 | 1995-02-28 | Biorex Kutato Fejlesztoe Kft | Process for production of composition against thromboembolytic conditions of circulating system and heart |
EP0347864A3 (en) * | 1988-06-24 | 1992-04-01 | Andries Johannes Cornelus Strydom | Anti-atherogenic agents |
WO1995015750A1 (en) * | 1993-12-10 | 1995-06-15 | Hashim Sami A | Reducing likelihood of vascular disorders in susceptible patients |
JP3119430B2 (ja) * | 1995-07-25 | 2000-12-18 | 大鵬薬品工業株式会社 | 水酸基ラジカル消去剤 |
LV11727B (en) * | 1995-08-21 | 1997-08-20 | Kalvins Ivars | Pharmaceutical composition |
US5880098A (en) * | 1996-04-12 | 1999-03-09 | Pharmacia & Upjohn Aktiebolag | Therapeutic treatment |
SE9601396D0 (sv) * | 1996-04-12 | 1996-04-12 | Dieter Haeussinger | New therapeutic treatment 2 |
US6008221A (en) * | 1996-11-06 | 1999-12-28 | Bristol-Myers Squibb Company | Method for treating Alzheimer's disease with folic acid |
US6162852A (en) | 1996-12-13 | 2000-12-19 | Isolyser Company, Inc. | Degradable polymers |
-
1999
- 1999-03-02 BE BE9900144A patent/BE1012495A3/fr not_active IP Right Cessation
-
2000
- 2000-03-01 IL IL14506800A patent/IL145068A0/xx unknown
- 2000-03-01 WO PCT/BE2000/000021 patent/WO2000051596A1/fr active IP Right Grant
- 2000-03-01 AT AT00907365T patent/ATE311226T1/de not_active IP Right Cessation
- 2000-03-01 EA EA200100925A patent/EA004047B1/ru not_active IP Right Cessation
- 2000-03-01 PL PL350408A patent/PL204560B1/pl not_active IP Right Cessation
- 2000-03-01 JP JP2000602064A patent/JP2002538113A/ja active Pending
- 2000-03-01 AU AU28979/00A patent/AU2897900A/en not_active Abandoned
- 2000-03-01 KR KR1020017011119A patent/KR100767270B1/ko not_active IP Right Cessation
- 2000-03-01 CA CA002362558A patent/CA2362558C/fr not_active Expired - Fee Related
- 2000-03-01 CN CNB008045054A patent/CN1194681C/zh not_active Expired - Fee Related
- 2000-03-01 MX MXPA01008426A patent/MXPA01008426A/es active IP Right Grant
- 2000-03-01 EP EP00907365A patent/EP1156796B1/fr not_active Expired - Lifetime
- 2000-03-01 DE DE60024415T patent/DE60024415T2/de not_active Expired - Lifetime
- 2000-03-01 HU HU0105397A patent/HUP0105397A3/hu unknown
- 2000-03-01 BR BR0008631-2A patent/BR0008631A/pt not_active Application Discontinuation
- 2000-03-01 NZ NZ513905A patent/NZ513905A/en unknown
- 2000-03-01 ES ES00907365T patent/ES2254144T3/es not_active Expired - Lifetime
-
2001
- 2001-08-31 US US09/945,391 patent/US6855734B2/en not_active Expired - Fee Related
-
2002
- 2002-05-28 HK HK02103986.8A patent/HK1044276B/zh not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
ATE311226T1 (de) | 2005-12-15 |
US6855734B2 (en) | 2005-02-15 |
PL204560B1 (pl) | 2010-01-29 |
ES2254144T3 (es) | 2006-06-16 |
CA2362558A1 (fr) | 2000-09-08 |
NZ513905A (en) | 2001-09-28 |
CA2362558C (fr) | 2009-06-02 |
KR20020021369A (ko) | 2002-03-20 |
DE60024415T2 (de) | 2006-09-21 |
DE60024415D1 (de) | 2006-01-05 |
HK1044276B (zh) | 2006-12-22 |
CN1194681C (zh) | 2005-03-30 |
US20020065320A1 (en) | 2002-05-30 |
EA004047B1 (ru) | 2003-12-25 |
HK1044276A1 (en) | 2002-10-18 |
JP2002538113A (ja) | 2002-11-12 |
AU2897900A (en) | 2000-09-21 |
KR100767270B1 (ko) | 2007-10-17 |
HUP0105397A3 (en) | 2003-03-28 |
WO2000051596A1 (fr) | 2000-09-08 |
EP1156796B1 (fr) | 2005-11-30 |
MXPA01008426A (es) | 2003-06-06 |
EP1156796A1 (fr) | 2001-11-28 |
BE1012495A3 (fr) | 2000-11-07 |
WO2000051596A9 (fr) | 2001-10-11 |
IL145068A0 (en) | 2002-06-30 |
PL350408A1 (en) | 2002-12-02 |
HUP0105397A2 (hu) | 2002-05-29 |
CN1342071A (zh) | 2002-03-27 |
BR0008631A (pt) | 2002-02-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200100925A1 (ru) | Применение глицинбетаина в качестве антитромботического средства | |
CL2004000376A1 (es) | Compuestos derivados de fenil propil amidas n-(aminoiminometil o aminometil) susttiuidas; compuestos intermediarios; composicion farmaceutica; y su uso para tratar un efecto patologico de la trombina, como trastornos tromboticos venosos o arteriales. | |
EA200401240A1 (ru) | Применение ингибиторов il-18 для лечения и/или профилактики заболеваний периферических сосудов | |
WO2010065077A3 (en) | Antagonists of il-6 to prevent or treat thrombosis | |
DE60312309D1 (de) | Verwendung von botulinum toxin zur behandlung von herz- und kreislaufskrankheiten | |
Carrijo et al. | Biological properties of the venom from the scorpionfish (Scorpaena plumieri) and purification of a gelatinolytic protease | |
CY1113705T1 (el) | Μεθοδοι για τη θεραπεια αιμορραγικων διαταραχων με τη χρηση θειωμενων πολυσακχαριτων | |
DE60229406D1 (de) | Verfahren zur behandlung oder verhinderung von vaskulärer entzündung mit sterol-absorbierungs- inhibitor(en) | |
DK0558529T3 (da) | Farmaceutisk præparat til behandling af forlænget koagulationstid | |
EA200300849A1 (ru) | Способы лечения или профилактики кожных заболеваний с помощью cd2-связывающих агентов | |
AU9576901A (en) | Preparation for the relief of disease | |
WO2003007921A3 (en) | Use of rhein or diacerhein compounds for the treatment or prevention of vascular diseases | |
EA200000059A1 (ru) | Блокада cd154 как лечение синдрома ингибирования терапевтических белков | |
EP1544214A4 (en) | Non-neutralizing anti-aPC antibodies | |
Mahadeswaraswamy et al. | Local tissue destruction and procoagulation properties of Echis carinatus venom: inhibition by Vitis vinifera seed methanol extract | |
Hasegawa | Clinical assessment of warfarin therapy in patients with maintenance dialysis-clinical efficacy, risks and development of calciphylaxis | |
DK0804254T3 (da) | Varmebehandling af blodplasmaproteiner | |
ME00015B (me) | Preparat za kateter i njegova upotreba | |
ATE498305T1 (de) | Vermeidung und behandlung von krankheiten, die mit der blutgerinnung in zusammenhang stehen | |
Chaves et al. | Intramuscular administration of antivenoms in experimental envenomation by Bothrops asper: comparison between Fab and IgG | |
EA200400751A1 (ru) | Применение дезоксипеганина для лечения клинической депрессии | |
DE60021111D1 (de) | Verwendung von fibrinolytischen metallproteinasen zur behandlung von blutgerinseln | |
JP2003286300A5 (ru) | ||
WO2000068264A3 (en) | A peptide inhibitor of fibrinogen blood clotting | |
ATE482705T1 (de) | Antibakterielle behandlung von osteoarthritis |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM |
|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): RU |